MarketCap
Facebook
X
Telegram
Celsion Corporation Total Shareholders Equity | CLSN
Annual Total Shareholders Equity Celsion Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.06 M | 4.24 M | 13.4 M | 29.3 M | 55.8 M | 18.6 M | 14.6 M | 20.9 M | 26.7 M | 6.73 M | 20.4 M | 32.8 M | 31.5 M | 12 M | 26.2 M | -4.58 M | 10 M |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 55.8 M | -4.58 M | 19.2 M |
Quarterly Total Shareholders Equity Celsion Corporation
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.24 M | 3.36 M | 13.4 M | 4.08 M | 2.66 M | 452 K | 4.24 M | 8.19 M | 3.74 M | 8.5 M | 13.4 M | 18.1 M | 21.5 M | 26.6 M | 29.3 M | 41.4 M | 47 M | 46.3 M | 55.8 M | 59.3 M | 64.1 M | 55 M | 18.6 M | 18.6 M | 18.6 M | 18.6 M | 14.6 M | 14.6 M | 14.6 M | 14.6 M | 20.9 M | 20.9 M | 20.9 M | 20.9 M | 26.7 M | 26.7 M | 26.7 M | 26.7 M | 6.73 M | 6.73 M | 6.73 M | 6.73 M | 20.4 M | 20.4 M | 20.4 M | 20.4 M | 32.8 M | 32.8 M | 32.8 M | 32.8 M | 31.5 M | 31.5 M | 31.5 M | 31.5 M | 12 M | 12 M | 12 M | 12 M | 26.2 M | 26.2 M | 26.2 M | 26.2 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 64.1 M | 452 K | 22.1 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Brickell Biotech
BBI
|
9.93 M | - | -5.38 % | $ 6.06 M |  USA |
 |
Applied Therapeutics
APLT
|
57 M | - | - | $ 8.42 M | USA |
 |
ESSA Pharma
EPIX
|
125 M | - | - | $ 8.86 M |  Canada |
 |
Generation Bio Co.
GBIO
|
86.2 M | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
-38.9 M | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
648 M | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
190 M | - | - | $ 2.36 B | USA |
 |
Annexon
ANNX
|
212 M | $ 4.21 | 4.99 % | $ 653 M | USA |
 |
AbbVie
ABBV
|
-3.27 B | $ 291.22 | 1.06 % | $ 515 B | USA |
 |
22nd Century Group
XXII
|
15.8 M | $ 1.56 | -19.17 % | $ 287 K | USA |
 |
Axon Enterprise
AXON
|
3.24 B | $ 313.68 | -18.01 % | $ 24.5 B | USA |
 |
Biogen
BIIB
|
18.3 B | $ 248.51 | 1.88 % | $ 36.4 B | USA |
 |
BioLineRx Ltd.
BLRX
|
23.3 M | $ 1.73 | -2.15 % | $ 4.26 B |  Israel |
 |
Theratechnologies
THTX
|
-25.3 M | - | - | $ 83.9 M | Canada |
 |
Exelixis
EXEL
|
2.16 B | $ 69.55 | 1.22 % | $ 18.9 B | USA |
 |
Geron Corporation
GERN
|
226 M | $ 0.99 | 3.97 % | $ 660 M | USA |
 |
Gilead Sciences
GILD
|
22.7 B | $ 166.9 | -0.4 % | $ 208 B | USA |
 |
Grifols, S.A.
GRFS
|
8.61 B | $ 8.46 | -0.12 % | $ 5.75 B |  Spain |
 |
Alnylam Pharmaceuticals
ALNY
|
789 M | $ 155.97 | -0.44 % | $ 20.4 B | USA |
 |
InflaRx N.V.
IFRX
|
41.6 M | $ 1.31 | -3.69 % | $ 88.1 M |  Germany |
 |
INmune Bio
INMB
|
23.5 M | $ 1.12 | -4.68 % | $ 27.7 M | USA |
 |
Insmed Incorporated
INSM
|
739 M | $ 114.55 | 5.32 % | $ 22.8 B | USA |
 |
Johnson & Johnson
JNJ
|
81.5 B | $ 274.89 | 0.95 % | $ 662 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
2.44 M | - | -3.76 % | $ 3.47 M | USA |
 |
Lineage Cell Therapeutics
LCTX
|
44.5 M | $ 1.02 | 3.75 % | $ 235 M | USA |
 |
BioVie
BIVI
|
19 M | $ 1.33 | 9.92 % | $ 1.96 M | USA |
 |
Longeveron
LGVN
|
5.68 M | $ 1.82 | 6.43 % | $ 32 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
18.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
TCR2 Therapeutics
TCRR
|
141 M | - | - | $ 58.1 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
992 M | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Mustang Bio
MBIO
|
9.53 M | $ 0.39 | 0.15 % | $ 1.91 M | USA |
 |
TFF Pharmaceuticals
TFFP
|
9.57 M | - | -60.05 % | $ 125 K | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
5.59 M | $ 1.63 | 1.87 % | $ 2.68 M | Israel |
 |
Mesoblast Limited
MESO
|
597 M | $ 14.26 | 1.13 % | $ 17.2 B |  Australia |
 |
Mirum Pharmaceuticals
MIRM
|
315 M | $ 93.81 | 0.28 % | $ 4.71 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
11.8 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
45.9 M | - | - | $ 521 M | USA |
 |
Codexis
CDXS
|
50.5 M | $ 1.09 | 6.37 % | $ 95 M | USA |
 |
MannKind Corporation
MNKD
|
-51 M | $ 3.91 | 4.0 % | $ 1.2 B | USA |
 |
MediciNova
MNOV
|
41.6 M | $ 1.44 | -0.69 % | $ 70.7 M | USA |
 |
Axcella Health
AXLA
|
4.16 M | - | -16.42 % | $ 249 M | USA |
 |
Merck & Co.
MRK
|
52.6 B | $ 146.81 | -0.07 % | $ 367 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
597 M | - | - | $ 2.02 B | USA |
 |
Tyme Technologies
TYME
|
80.1 M | - | 8.07 % | $ 54 M | USA |
 |
Curis
CRIS
|
5.46 M | $ 0.88 | 3.67 % | $ 11.6 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
6.79 M | $ 34.99 | 3.77 % | $ 147 M | USA |
 |
CorMedix
CRMD
|
405 M | $ 5.31 | 1.43 % | $ 383 K | USA |
 |
Novartis AG
NVS
|
46.5 B | $ 162.64 | 0.44 % | $ 315 B |  Schweiz |
 |
CRISPR Therapeutics AG
CRSP
|
1.92 B | $ 50.09 | 3.15 % | $ 4.5 B | Schweiz |